You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlclometasone
Accession NumberDB00240  (APRD00783)
TypeSmall Molecule
GroupsApproved
DescriptionAlclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent. [Wikipedia]
Structure
Thumb
Synonyms
(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
7α-Chloro-16α-methylprednisolone
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AclovateCream.5 mg/gTopicalPharmaDerm, A division of Nycomed US Inc.2009-09-01Not applicableUs
AclovateOintment.5 mg/gTopicalPharmaDerm, A division of Nycomed US Inc.2009-10-01Not applicableUs
Alclometasone DipropionateOintment.5 mg/gTopicalGlenmark Pharmaceuticals Inc., Usa2009-07-30Not applicableUs
Alclometasone DipropionateCream.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2005-07-12Not applicableUs
Alclometasone DipropionateCream.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2005-09-15Not applicableUs
Alclometasone DipropionateCream.5 mg/gTopicalGlenmark Pharmaceuticals Inc., Usa2009-06-23Not applicableUs
Alclometasone DipropionateOintment.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2005-07-18Not applicableUs
Alclometasone DipropionateOintment.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2004-07-29Not applicableUs
Alclometasone DipropionateCream.5 mg/gTopicalPhysicians Total Care, Inc.2009-06-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Alclometasone dipropionate
66734-13-2
Thumb
  • InChI Key: DJHCCTTVDRAMEH-DUUJBDRPSA-N
  • Monoisotopic Mass: 520.2227812
  • Average Mass: 521.05
DBSALT000893
Categories
UNII136H45TB7B
CAS number67452-97-5
WeightAverage: 408.916
Monoisotopic: 408.170351745
Chemical FormulaC22H29ClO5
InChI KeyFJXOGVLKCZQRDN-PHCHRAKRSA-N
InChI
InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1
IUPAC Name
(1S,2R,9R,10S,11S,13R,14R,15S,17S)-9-chloro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])[[email protected]](Cl)CC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Structured Indications
PharmacodynamicsAlclometasone is a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Alclometasone is a selective glucocorticoid receptor agonist.
Mechanism of actionThe mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Alclometasone initially binds the corticosteroid receptor. This complex migrates to the nucleus where it binds to different glucocorticoid response elements on the DNA. This in turn enhances and represses various genes, especially those involved in inflammatory pathways.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionTopical corticosteroids can be absorbed from normal intact skin. Studies have shown that approximately 3% of steroid is absorbed during 8 hours of contact with intact skin of normal volunteers.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include suppression of adrenal glands, temporary decrease in white blood cell counts, symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), and increased susceptibility to infection.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Alclometasone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alclometasone.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Alclometasone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alclometasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Alclometasone.Approved
AldesleukinAlclometasone may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Alclometasone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Alclometasone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Alclometasone can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Alclometasone.Approved
AmiodaroneThe metabolism of Alclometasone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BAlclometasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Alclometasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Alclometasone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Alclometasone.Approved, Investigational
AprepitantThe serum concentration of Alclometasone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Alclometasone.Approved, Investigational
AtazanavirThe metabolism of Alclometasone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Alclometasone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Alclometasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alclometasone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Alclometasone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alclometasone.Approved, Investigational
BazedoxifeneThe serum concentration of Alclometasone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideAlclometasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alclometasone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Alclometasone.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Alclometasone.Investigational
BexaroteneThe serum concentration of Alclometasone can be decreased when it is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe bioavailability of Alclometasone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Alclometasone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Alclometasone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Alclometasone can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alclometasone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Alclometasone.Investigational
BumetanideAlclometasone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Alclometasone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Alclometasone can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe metabolism of Alclometasone can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Alclometasone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alclometasone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Alclometasone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alclometasone.Approved, Investigational
CeritinibThe serum concentration of Alclometasone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Alclometasone.Approved, Vet Approved
ChlorothiazideAlclometasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Alclometasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneAlclometasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe metabolism of Alclometasone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Alclometasone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Alclometasone.Approved
ClotrimazoleThe metabolism of Alclometasone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Alclometasone can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Alclometasone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Alclometasone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Alclometasone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Alclometasone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Alclometasone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Alclometasone.Investigational
CyclosporineThe metabolism of Alclometasone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Alclometasone.Investigational
DabrafenibThe serum concentration of Alclometasone can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Alclometasone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Alclometasone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Alclometasone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Alclometasone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Alclometasone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Alclometasone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Alclometasone.Investigational
DexamethasoneThe serum concentration of Alclometasone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Alclometasone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alclometasone.Approved, Vet Approved
DienestrolThe serum concentration of Alclometasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Alclometasone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alclometasone.Approved
DihydroergotamineThe metabolism of Alclometasone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneAlclometasone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Alclometasone can be decreased when combined with Diltiazem.Approved
DonepezilThe risk or severity of adverse effects can be increased when Alclometasone is combined with Donepezil.Approved
DoxycyclineThe metabolism of Alclometasone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Alclometasone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Alclometasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Alclometasone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Alclometasone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Alclometasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Alclometasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Alclometasone is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Alclometasone can be decreased when it is combined with Efavirenz.Approved, Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Alclometasone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Alclometasone.Approved
ErythromycinThe metabolism of Alclometasone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Alclometasone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Alclometasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Alclometasone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Alclometasone can be increased when it is combined with Estrone.Approved
Etacrynic acidAlclometasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Alclometasone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Alclometasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Alclometasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alclometasone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alclometasone.Approved, Investigational
EtravirineThe serum concentration of Alclometasone can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Alclometasone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Alclometasone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alclometasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Alclometasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Alclometasone is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Alclometasone.Approved, Withdrawn
FluconazoleThe metabolism of Alclometasone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Alclometasone.Vet Approved
FluoxymesteroneAlclometasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alclometasone.Approved, Investigational
FluvoxamineThe metabolism of Alclometasone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Alclometasone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Alclometasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Alclometasone can be increased when combined with Fosphenytoin.Approved
FurosemideAlclometasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Alclometasone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Alclometasone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Alclometasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Alclometasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Alclometasone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Alclometasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Alclometasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Alclometasone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Alclometasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Alclometasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alclometasone.Approved, Investigational
HydrochlorothiazideAlclometasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAlclometasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alclometasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Alclometasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Alclometasone.Approved
IdelalisibThe serum concentration of Alclometasone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Alclometasone can be decreased when combined with Imatinib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Alclometasone.Approved
IndapamideAlclometasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Alclometasone can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alclometasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alclometasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Alclometasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Alclometasone is combined with INGN 225.Investigational
IsavuconazoniumThe metabolism of Alclometasone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Alclometasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Alclometasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alclometasone.Withdrawn
IsradipineThe metabolism of Alclometasone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Alclometasone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Alclometasone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alclometasone.Experimental
KetoconazoleThe metabolism of Alclometasone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Alclometasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Alclometasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Alclometasone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alclometasone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Lomefloxacin.Approved
LopinavirThe metabolism of Alclometasone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alclometasone.Approved
LovastatinThe metabolism of Alclometasone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alclometasone.Approved
LuliconazoleThe serum concentration of Alclometasone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Alclometasone can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alclometasone.Approved, Investigational
MagaldrateThe bioavailability of Alclometasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Alclometasone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Alclometasone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Alclometasone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alclometasone.Approved
Magnesium TrisilicateThe bioavailability of Alclometasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Alclometasone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alclometasone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alclometasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alclometasone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alclometasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alclometasone.Approved
MestranolThe serum concentration of Alclometasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Alclometasone.Withdrawn
MethallenestrilThe serum concentration of Alclometasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Alclometasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideAlclometasone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneAlclometasone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneAlclometasone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Alclometasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Minaprine.Approved
MitotaneThe serum concentration of Alclometasone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Alclometasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alclometasone.Investigational
ModafinilThe serum concentration of Alclometasone can be decreased when it is combined with Modafinil.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alclometasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alclometasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Alclometasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Alclometasone.Investigational
NafcillinThe serum concentration of Alclometasone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Alclometasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Alclometasone is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Alclometasone.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Alclometasone.Investigational
NefazodoneThe metabolism of Alclometasone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Alclometasone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alclometasone.Approved
NetupitantThe serum concentration of Alclometasone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Alclometasone can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Alclometasone is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alclometasone.Approved
NilotinibThe metabolism of Alclometasone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alclometasone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alclometasone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ofloxacin.Approved
OlaparibThe metabolism of Alclometasone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alclometasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alclometasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Alclometasone.Vet Approved
OsimertinibThe serum concentration of Alclometasone can be increased when it is combined with Osimertinib.Approved
OxandroloneAlclometasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alclometasone.Approved
OxymetholoneAlclometasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alclometasone.Withdrawn
PalbociclibThe serum concentration of Alclometasone can be increased when it is combined with Palbociclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Alclometasone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Alclometasone can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Alclometasone can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Alclometasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alclometasone.Approved, Vet Approved
PhenytoinThe metabolism of Alclometasone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alclometasone.Approved, Investigational
PiretanideAlclometasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alclometasone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alclometasone.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Alclometasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideAlclometasone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Alclometasone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Alclometasone can be increased when combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Alclometasone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alclometasone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Alclometasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Alclometasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneAlclometasone may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rabies vaccine.Approved
RanolazineThe metabolism of Alclometasone can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Alclometasone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alclometasone.Experimental, Investigational
RifabutinThe metabolism of Alclometasone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Alclometasone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Alclometasone can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Alclometasone can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Alclometasone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Alclometasone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alclometasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alclometasone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Alclometasone.Approved
SaquinavirThe metabolism of Alclometasone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Alclometasone.Approved
SecoisolariciresinolThe serum concentration of Alclometasone can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alclometasone.Approved, Investigational
SildenafilThe metabolism of Alclometasone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Alclometasone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Alclometasone can be increased when it is combined with Simeprevir.Approved
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Alclometasone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Alclometasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Alclometasone.Investigational
St. John's WortThe serum concentration of Alclometasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololAlclometasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Alclometasone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alclometasone.Approved
SulfisoxazoleThe metabolism of Alclometasone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Alclometasone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Alclometasone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Alclometasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Alclometasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Alclometasone.Approved
TelithromycinThe metabolism of Alclometasone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Alclometasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Alclometasone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alclometasone.Approved
TestosteroneAlclometasone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Alclometasone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alclometasone.Approved
TiboloneThe serum concentration of Alclometasone can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Alclometasone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Alclometasone.Investigational
TocilizumabThe serum concentration of Alclometasone can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alclometasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alclometasone.Approved
TorasemideAlclometasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Alclometasone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Alclometasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideAlclometasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Alclometasone.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Alclometasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Alclometasone.Investigational, Withdrawn
VenlafaxineThe metabolism of Alclometasone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Alclometasone can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Alclometasone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinAlclometasone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alclometasone.Approved
ZeranolThe serum concentration of Alclometasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Alclometasone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Alclometasone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alclometasone.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesS01BA10D07AB10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (191 KB)
MSDSDownload (26.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.9518
Caco-2 permeable+0.6337
P-glycoprotein substrateSubstrate0.7572
P-glycoprotein inhibitor INon-inhibitor0.8049
P-glycoprotein inhibitor IINon-inhibitor0.8763
Renal organic cation transporterNon-inhibitor0.8262
CYP450 2C9 substrateNon-substrate0.8524
CYP450 2D6 substrateNon-substrate0.9027
CYP450 3A4 substrateSubstrate0.717
CYP450 1A2 substrateNon-inhibitor0.9228
CYP450 2C9 inhibitorNon-inhibitor0.9215
CYP450 2D6 inhibitorNon-inhibitor0.9372
CYP450 2C19 inhibitorNon-inhibitor0.8962
CYP450 3A4 inhibitorNon-inhibitor0.7736
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8568
Ames testNon AMES toxic0.8448
CarcinogenicityNon-carcinogens0.9132
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.2398 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9651
hERG inhibition (predictor II)Non-inhibitor0.6522
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Nycomed us inc
  • Altana inc
  • Glenmark generics ltd
  • Taro pharmaceuticals usa inc
  • Glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
CreamTopical.5 mg/g
OintmentTopical.5 mg/g
Prices
Unit descriptionCostUnit
Aclovate 0.05% Ointment 60 gm Tube141.1USD tube
Aclovate 0.05% Cream 60 gm Tube103.1USD tube
Aclovate 0.05% Cream 45 gm Tube81.19USD tube
Aclovate 0.05% Cream 15 gm Tube54.54USD tube
Aclovate 0.05% Ointment 15 gm Tube52.99USD tube
Alclometasone Dipropionate 0.05% Cream 60 gm Tube52.99USD tube
Alclometasone Dipropionate 0.05% Cream 45 gm Tube41.31USD tube
Alclometasone Dipropionate 0.05% Ointment 60 gm Tube39.27USD tube
Alclometasone Dipropionate 0.05% Cream 15 gm Tube19.81USD tube
Alclometasone Dipropionate 0.05% Ointment 15 gm Tube16.99USD tube
Aclovate 0.05% cream2.91USD g
Alclometasone dipro 0.05% crm1.21USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.137 mg/mLALOGPS
logP2.11ALOGPS
logP1.68ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity107.61 m3·mol-1ChemAxon
Polarizability42.62 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 7-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl chloride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Labeur M, Holsboer F: Molecular mechanisms of glucocorticoid receptor signaling. Medicina (B Aires). 2010;70(5):457-62. [PubMed:20920967 ]
  2. Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. [PubMed:9891987 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34. [PubMed:12167569 ]
  2. Cooper BW, Cho TM, Thompson PM, Wallace AD: Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of PXR expression. Toxicol Sci. 2008 Jun;103(2):268-77. doi: 10.1093/toxsci/kfn047. Epub 2008 Mar 10. [PubMed:18332045 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23